Skip to main content

Table 3 Clinicopathological correlation with KIAA1549-BRAF fusion status in patients with LGG

From: Incidence of kiaa1549-braf fusion gene in Egyptian pediatric low grade glioma

  Total Positive Negative p-value
Tumor examined 60 34(56.6%) 26(43.3%)  
Tumor location     
Cerebellar 37(61%) 26(70.2%) 11(29.2%) 0.008*
Lobar 15(25%) 5(33.3%) 10(66.6%) 0.068
Spinal cord 3(5%) 2(66.6%) 1(33.3%) 1
Optic pathway 2(3.3%) 0 2(100%) 0.18
Pathology     
PAs 31(51.6%) 23(74.2%) 8(25.8%) 0.008*
PMAs 15(25%) 9(60%) 6(40%) 0.769
DAs 3(5%) 0 3(100%)  
PXA 2(3.3%) 0 2(100%)  
LGGN 9(15%) 2(22.2%) 7(77.7%) 0.032*
Gender     
Females 26(43.3%) 16(61.5%) 10(38.4%) 0.79
Males 34(56.5%) 19(55.8%) 15(44.1%)  
  1. PAs, pilocytic astrocyoma; PMAs, pilomyxoid astrocyoma; PXA, pleomophicxantho astrocytoma; LGGN (low grade glioneuronal); DAs, (diffuse astrocytom)a. *Fisher’s exact test (P > 0.05).